Lack of α2-antiplasmin improves cutaneous wound healing via over-released vascular endothelial growth factor-induced angiogenesis in wound lesions

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 7, 2006, Pages 1602-1610

  Kanno, Yosuke ^a,b   Hirade, K ^a   Ishisaki, A ^c   Nakajima, K ^d   Suga, H ^e   Into, T ^b   Matsushita, K ^b   Okada, K ^f   Matsuo, O ^f   Matsuno, H ^f  

^a Faculty of Pharmaceutical Science   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d NATIONAL AGRICULTURAL RESEARCH CENTER FOR HOKKAIDO REGION   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

antiplasmin; Angiogenesis; VEGF

Indexed keywords

ALPHA 2 ANTIPLASMIN; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VON WILLEBRAND FACTOR; ANTIPLASMIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL CULTURE; CONTROLLED STUDY; FIBROBLAST; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; WOUND CLOSURE; WOUND HEALING; ANIMAL; COMPARATIVE STUDY; GENETICS; INJURY; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SKIN; TIME;

ANIMALS; ANTIPLASMIN; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; SKIN; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING; WOUNDS AND INJURIES;

EID: 33745239244     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01978.x     Document Type: Article

References (49)

1. Collen D. Towards improved thrombolytic therapy. Lancet 1993; 342: 34-6.
2. Grondahl-Hansen J, Lund LR, Ralfkiaer E, Ottevanger V, Dano K. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol 1988; 90: 790-5.
3. Schafer BM, Maier K, Eickhoff U, Todd RF, Kramer MD. Plasminogen activation in healing human wounds. Am J Pathol 1994;144: 1269-80.
4. Pepper MS, Vassalli J-D, Montesano R, Orci L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987; 105: 2535-41.
5. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
6. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: Light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-9.
7. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-16.
8. Lijnen HR, De Cock F, Van Hoef B, Schlott B, Collen D. Characterization of the interaction between plasminogen and staphylokinase. Eur J Biochem 1994; 224: 143-9.
9. Carmeliet P, Collen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Semin Thromb Hemost 1996; 22: 525-42.
10. Montes R, Paramo JA, Angles-Cano E, Rocha E. Development and clinical application of a new ELISA assay to determine plasmin-alpha2-antiplasmin complexes in plasma. Br J Haematol 1996; 92: 979-85.
11. Bayes-Genis A, Guindo J, Oliver A, Badimon L, Fiol M, Mateo J, Souto JC, Dominguez JM, Fontcuberta J, Bayes de Luna A. Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina. Thromb Haemost 1999; 81: 979-85.
12. Clark RF, Henson PM. The Molecular and Cellular Biology of Wound Repair. New York: Plenum Publishing Corp., 1988.
13. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005; 9: 777-94.
14. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83: 835-70.
15. McColl BK, Baldwin ME, Roufail S, Freeman C, Moritz RL, Simpson RJ, Alitalo K, Stacker SA, Achen MG. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med 2003; 198: 863-8.
16. Matsuno H, Ishisaki A, Nakajima K, Okada K, Ueshima S, Matsuo O, Kozawa O. Lack of alpha 2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice. Blood 2003; 102: 3621-8.
17. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
18. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-7.
19. Connolly DT, Olander J, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R, Feder J. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989; 264: 20017-24.
20. Corral CJ, Siddiqui A, Wu L, Farrell CL, Lyons D, Mustoe TA. Vascular endothelial growth factor is more important than basic fibroblastic growth factor during ischemic wound healing. Arch Surg 1999; 134: 200-5.
21. Howdieshell TR, Callaway D, Webb WL, Gaines MD, Procter Jr CD, Sathyanarayana MD, Pollock JS, Brock TL, McNeil PL. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 2001; 96: 173-82.
22. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152: 1445-52.
23. Okada K, Lijnen HR, Dewerchin M, Belayew A, Matsuo O, Collen D, Bernaerts R. Characterization and targeting of the murine alpha2-antiplasmin gene. Thromb Haemost 1997; 78: 1104-10.
24. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999; 93: 2274-81.
25. Yoshida S, Yamaguchi Y, Itami S, Yoshikawa K, Tabata Y, Matsumoto K, Nakamura T. Neutralization of hepatocyte growth factor leads to retarded cutaneous wound healing associated with decreased neovascularization and granulation tissue formation. J Invest Dermatol 2003; 120: 335-43.
26. Anand RJ, Paust H-J, Altenpohl K, Mukhopadhyay AK. Regulation of vascular endothelial growth factor production by Leydig cells in vitro: the role of protein kinase A and mitogen-activated protein kinase cascade. Biol Reprod 2003; 68: 1663-73.
27. Ham RG. Dermal fibroblasts. Methods Cell Biol 1980; 21A: 255-76.
28. Matsuno H, Kozawa O, Yoshimi N, Akamatsu S, Hara A, Mori H, Okada K, Ueshima S, Matsuo O, Uematsu T. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. Blood 2002; 100: 2487-93.
29. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002; 39: 225-37.
30. Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D'Amore PA. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 1996; 271: 3877-83.
31. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114: 521-32.
32. Claffey KP, Wilison W, Spiegelman BM. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 1992; 267: 16317-22.
33. Anonick PK, Gonias SL. Soluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin. Biochem J 1991; 275: 53-9.
34. Rouy D, Angles-Cano E. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin. Biochem J 1990; 271: 51-7.
35. Schaefer BM, Maier K, Eickhoff U, Bechtel M, Kramer MD. Alpha2-antiplasmin and plasminogen activator inhibitors in healing human skin wounds. Arch Dermatol Res 1996; 288: 122-8.
36. Romer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Dano K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996; 2: 287-92.
37. Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899-904.
38. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003; 47: 149-61.
39. Lang RA, Metcalf D, Cuthbertson RA, Lyons I, Stanley E, Kelso A, Kannourakis G, Williamson DJ, Klintworth GK, Gonda TJ, Dunn AR. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 1987; 51: 675-86.
40. Metcalf D, Moore JG. Divergent disease patterns in granulocyte-macrophage colony-stimulating factor transgenic mice associated with different transgene insertion sites. Proc Natl Acad Sci USA 1988; 85: 7767-71.
41. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35-65.
42. Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801-4.
43. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999; 94: 1561-7.
44. Tanaka T, Kanai H, Sekiguchi K, Aihara Y, Yokoyama T, Arai M, Kanda T, Nagai R, Kurabayashi M. Induction of VEGF gene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J Mol Cell Cardiol 2000; 32: 1955-67.
45. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H, Tarnawski AS. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001; 286: 923-8.
46. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4: 1317-26.
47. Brown LF, Van der Water L, Harvey VS, Dvorak HF. Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol 1988; 130: 455-65.
48. Breuing K, Eriksson E, Liu P, Miller DR. Healing of partial thickness porcine skin wounds in a liquid environment. J Surg Res 1992; 52: 50-8.
49. Howes S, Harvey SC. Healing of wounds as determined by their tensile strength. JAMA 1929; 92: 42.